Mesa Laboratories, Inc.
MLAB- 1M
- -2.8%
Mesa Laboratories, Inc. in brief
Mesa Laboratories, Inc. is a listed company in the Scientific Technical Instruments industry, based in Lakewood, Colorado, USA. Its market value was $726 M on 28 October 2026, which makes it the 10,912th largest listed company in the world and the 2,268th largest in the USA on this site. In the year to March 2026 it had sales of $249 M and a net profit of $7 M, about 3 cents of profit for every dollar of sales. It employs about 347 people and Siddhartha Kadia is its chief executive. Its largest product and service lines by sales in 2026 were Consumables (59%) and Hardware and Software (23%). By market, the largest shares of its 2026 sales came from USA (47%) and China (8%). Its shares trade under the symbol MLAB (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Mesa Laboratories, Inc.
Mesa Laboratories Develops, Manufactures and Markets, high quality process validation and monitoring instruments and consumables company. The company products are used to assure product quality, control manufacturing processes and to solve problems in niche markets in healthcare, industrial, pharmaceutical, medical and food processing applications. The headquarters is in USA.
Mesa Laboratories, Inc. timeline
- 1995
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 💰Record revenue of $249 millionFY2025, the highest of the 8 years on record.
- 💰Record net income of $7 millionFY2025, the highest profit of the 4 years on record.
Events of Mesa Laboratories, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,996 (Jan 2020) · #1,872 (Jan 2021) · #2,063 (Jan 2022) · #2,123 (Dec 2022) · #2,406 (Jul 2023) · #2,466 (Jan 2024) · #1,254 (Mar 2026) · #2,433 (Aug 2026) · #2,262 (Sep 2026) · #2,270 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 109.1×
- Price / sales (TTM)
- 2.9×
- Price / book
- 3.9×
- Free cash flow yield
- 5.4%
- Net margin (TTM)
- 2.6%
- Operating margin
- 7.4%
- Return on equity
- 3.6%
- Liabilities / assets
- 56.5%
- Net debt
- $41M
- Payout ratio
- 52.9%
- Revenue growth
- +3.4%
- R&D / revenue
- 8.2%
- Revenue per employee
- $718 K
- Profit per employee
- $19 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $249M | +3.4% | $19M | $7M | 2.7% |
| Mar 2025 | $241M | +11.5% | $16M | $-2M | -0.8% |
| Mar 2024 | $216M | -1.3% | $-272M | $-254M | -117.6% |
| Mar 2023 | $219M | +18.8% | $3M | $1M | 0.4% |
| Mar 2022 | $184M | +37.6% | $5M | $2M | 1.0% |
| Mar 2021 | $134M | +13.8% | $12M | $3M | 2.4% |
| Mar 2020 | $118M | +14.1% | $8M | — | — |
| Mar 2019 | $103M | — | $10M | — | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2026 | $43M | $3M | $40M | $1.21 | $0.64 |
| Mar 2025 | $47M | $4M | $43M | $-0.36 | $0.64 |
| Mar 2024 | $44M | $3M | $42M | $-47.20 | $0.64 |
| Mar 2023 | $28M | $5M | $23M | $0.17 | $0.64 |
| Mar 2022 | $39M | $4M | $35M | $0.35 | $0.64 |
| Mar 2021 | $37M | $2M | $35M | $0.64 | $0.64 |
| Mar 2020 | $27M | $2M | $25M | $0.41 | $0.64 |
| Mar 2019 | $31M | $1M | $29M | $1.86 | $0.64 |
Quarterly results
Latest quarter to Sep 2026: revenue $62M (+2.6% on a year earlier), net income $4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 20268-KCurrent reportResults of operations
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Oct 13, 20268-KCurrent reportRestructuring costs · Regulation FD disclosure
- Sep 8, 20268-KCurrent reportShareholder vote
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations
- Jul 30, 20268-KCurrent report
- Jul 22, 2026DEF 14AProxy statement
- Jun 15, 20268-KCurrent reportDirectors or officers changed
- Jun 3, 202610-KAnnual report · period to Mar 2026
- May 27, 20268-KCurrent reportResults of operations
- Mar 23, 20268-KCurrent reportDirectors or officers changed
Official filings of Mesa Laboratories, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $249 M
- Operating income
- $19 M
- Net income
- $7 M
For year ending March-2026 · source: SEC filing
Balance sheet
- Total assets
- $428 M
- Total liabilities
- $242 M
- Total equity
- $186 M
As of March-2026
Top 100 institutional investors in Mesa Laboratories, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Long Path Partners LP | 480,169 | +3,043 (+0.64%) | 8.54% | $62 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 457,599 | +17,047 (+3.87%) | 8.14% | $59 M | Nov 13, 2026 |
| 3 | Wasatch Advisors LP | 387,129 | +271,461 (+234.69%) | 6.89% | $50 M | Oct 13, 2026 |
| 4 | Victory Capital Management Inc | 276,565 | New | 4.92% | $36 M | Nov 10, 2026 |
| 5 | Vanguard Capital Management LLC | 236,214 | -1,243 (-0.52%) | 4.20% | $31 M | Nov 13, 2026 |
| 6 | Raymond James Financial Inc | 175,079 | +25,142 (+16.77%) | 3.12% | $23 M | Nov 12, 2026 |
| 7 | Arrowstreet Capital, Limited Partnership | 173,231 | New | 3.08% | $23 M | Nov 13, 2026 |
| 8 | Geode Capital Management, LLC | 165,736 | +26,054 (+18.65%) | 2.95% | $22 M | Nov 6, 2026 |
| 9 | Dimensional Fund Advisors LP | 163,907 | +15,512 (+10.45%) | 2.92% | $21 M | Nov 4, 2026 |
| 10 | Jacobs Levy Equity Management, Inc | 145,570 | +14,732 (+11.26%) | 2.59% | $19 M | Nov 16, 2026 |
| 11 | Kennedy Capital Management LLC | 143,200 | +4,899 (+3.54%) | 2.55% | $19 M | Nov 13, 2026 |
| 12 | Morgan Stanley | 140,015 | -16,964 (-10.81%) | 2.49% | $18 M | Nov 13, 2026 |
| 13 | State Street Corp | 135,509 | +11,217 (+9.02%) | 2.41% | $18 M | Nov 12, 2026 |
| 14 | Ranger Investment Management, L.P. | 131,431 | -42,557 (-24.46%) | 2.34% | $17 M | Nov 6, 2026 |
| 15 | William Blair Investment Management, LLC | 130,323 | New | 2.32% | $17 M | Nov 6, 2026 |
| 16 | Diamond Hill Capital Management, LLC (Investment Advisor) | 130,173 | -25,598 (-16.43%) | 2.32% | $17 M | Nov 10, 2026 |
| 17 | AQR Capital Management LLC | 129,111 | -74,628 (-36.63%) | 2.30% | $17 M | Nov 16, 2026 |
| 18 | D. E. Shaw & Co., Inc. | 127,505 | +45,750 (+55.96%) | 2.27% | $17 M | Nov 16, 2026 |
| 19 | Two Sigma Investments, LP | 119,478 | +90,239 (+308.63%) | 2.13% | $16 M | Nov 16, 2026 |
| 20 | Topline Capital Management, LLC | 95,499 | +93,125 (+3922.70%) | 1.70% | $12 M | Nov 16, 2026 |
| 21 | Crawford Investment Counsel Inc | 90,060 | -8,745 (-8.85%) | 1.60% | $12 M | Nov 16, 2026 |
| 22 | Jane Street Group, LLC | 85,367 | +13,787 (+19.26%) | 1.52% | $11 M | Nov 12, 2026 |
| 23 | Vanguard Portfolio Management LLC | 84,065 | +14,715 (+21.22%) | 1.50% | $11 M | Nov 13, 2026 |
| 24 | Russell Investments Group, Ltd. | 71,823 | -50,022 (-41.05%) | 1.28% | $9 M | Nov 6, 2026 |
| 25 | Northern Trust Corp | 67,078 | +1,333 (+2.03%) | 1.19% | $9 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Meros Investment Management, LP | 62,594 | -5,368 (-7.90%) | 1.11% | $8 M | Nov 17, 2026 |
| 27 | Gabelli Funds LLC | 62,475 | -24 (-0.04%) | 1.11% | $8 M | Nov 12, 2026 |
| 28 | FMR LLC | 61,238 | -27,619 (-31.08%) | 1.09% | $8 M | Nov 10, 2026 |
| 29 | Charles Schwab Investment Management Inc | 52,115 | -2,348 (-4.31%) | 0.93% | $7 M | Nov 16, 2026 |
| 30 | Bank of New York Mellon Corp | 45,458 | -144 (-0.32%) | 0.81% | $6 M | Nov 5, 2026 |
| 31 | Goldman Sachs Group Inc | 45,192 | -19,130 (-29.74%) | 0.80% | $6 M | Nov 16, 2026 |
| 32 | Royce & Associates LP | 39,598 | -73,797 (-65.08%) | 0.70% | $5 M | Nov 9, 2026 |
| 33 | Vanguard Fiduciary Trust Co | 39,354 | -182 (-0.46%) | 0.70% | $5 M | Nov 13, 2026 |
| 34 | Man Group plc | 33,404 | +9,334 (+38.78%) | 0.59% | $4 M | Nov 16, 2026 |
| 35 | Janus Henderson Group Ltd. | 31,869 | — | 0.57% | $4 M | Nov 16, 2026 |
| 36 | Principal Financial Group Inc | 30,421 | +18,352 (+152.06%) | 0.54% | $4 M | Nov 2, 2026 |
| 37 | Aberdeen Group plc | 26,005 | New | 0.46% | $3 M | Nov 10, 2026 |
| 38 | XTX Topco Ltd | 25,979 | +8,504 (+48.66%) | 0.46% | $3 M | Nov 16, 2026 |
| 39 | BBR Partners, LLC | 25,195 | 0 (0.00%) | 0.45% | $3 M | Nov 16, 2026 |
| 40 | American Century Companies Inc | 23,532 | +3,168 (+15.56%) | 0.42% | $3 M | Nov 12, 2026 |
| 41 | HRT Financial LP | 22,249 | New | 0.40% | $3 M | Nov 13, 2026 |
| 42 | Quadrature Capital Ltd | 21,886 | +14,204 (+184.90%) | 0.39% | $3 M | Nov 13, 2026 |
| 43 | Bank Of America Corp /de/ | 20,901 | -29,051 (-58.16%) | 0.37% | $3 M | Nov 16, 2026 |
| 44 | State Of Wisconsin Investment Board | 19,630 | +724 (+3.83%) | 0.35% | $3 M | Nov 16, 2026 |
| 45 | Rice Hall James & Associates, LLC | 19,135 | +167 (+0.88%) | 0.34% | $2 M | Nov 16, 2026 |
| 46 | Qube Research & Technologies Ltd | 18,704 | -18,698 (-49.99%) | 0.33% | $2 M | Nov 13, 2026 |
| 47 | Segall Bryant & Hamill, LLC | 18,139 | +31 (+0.17%) | 0.32% | $2 M | Nov 16, 2026 |
| 48 | Ameriprise Financial Inc | 18,056 | New | 0.32% | $2 M | Nov 16, 2026 |
| 49 | King Luther Capital Management Corp | 17,411 | 0 (0.00%) | 0.31% | $2 M | Nov 5, 2026 |
| 50 | Los Angeles Capital Management LLC | 15,875 | +8,487 (+114.88%) | 0.28% | $2 M | Nov 12, 2026 |
| 51 | Public Sector Pension Investment Board | 15,605 | New | 0.28% | $2 M | Nov 10, 2026 |
| 52 | State Board Of Administration Of Florida Retirement System | 15,124 | +9,679 (+177.76%) | 0.27% | $2 M | Nov 13, 2026 |
| 53 | Creative Planning | 14,717 | -1,898 (-11.42%) | 0.26% | $2 M | Nov 2, 2026 |
| 54 | BNP Paribas Financial Markets | 13,989 | +13,000 (+1314.46%) | 0.25% | $2 M | Nov 12, 2026 |
| 55 | Nuveen, LLC | 13,836 | -60 (-0.43%) | 0.25% | $2 M | Nov 10, 2026 |
| 56 | UBS Group AG | 13,064 | +5,291 (+68.07%) | 0.23% | $2 M | Nov 10, 2026 |
| 57 | Royal Bank Of Canada | 12,115 | -2,688 (-18.16%) | 0.22% | $2 M | Nov 16, 2026 |
| 58 | Wells Fargo & Company/mn | 11,023 | -3,363 (-23.38%) | 0.20% | $1 M | Nov 16, 2026 |
| 59 | Invesco Ltd. | 10,956 | -906 (-7.64%) | 0.19% | $1 M | Nov 12, 2026 |
| 60 | Globeflex Capital L P | 10,838 | -743 (-6.42%) | 0.19% | $1 M | Nov 16, 2026 |
| 61 | Martingale Asset Management L P | 10,828 | New | 0.19% | $1 M | Nov 12, 2026 |
| 62 | Stifel Financial Corp | 9,977 | -1,225 (-10.94%) | 0.18% | $1 M | Nov 12, 2026 |
| 63 | Franklin Templeton Inc | 9,911 | -11,994 (-54.75%) | 0.18% | $1 M | Nov 12, 2026 |
| 64 | Envestnet Asset Management Inc | 8,681 | -135 (-1.53%) | 0.15% | $1 M | Nov 16, 2026 |
| 65 | Quantinno Capital Management LP | 8,368 | +1,301 (+18.41%) | 0.15% | $1 M | Nov 13, 2026 |
| 66 | GAMCO Investors, Inc. Et Al | 8,340 | 0 (0.00%) | 0.15% | $1 M | Nov 12, 2026 |
| 67 | Evolve Private Wealth, LLC | 7,976 | New | 0.14% | $1 M | Nov 13, 2026 |
| 68 | B. Metzler seel. Sohn & Co. AG | 7,820 | New | 0.14% | $1 M | Oct 30, 2026 |
| 69 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 7,583 | +1,976 (+35.24%) | 0.13% | $1 M | Nov 16, 2026 |
| 70 | CM Wealth Advisors LLC | 7,571 | -770 (-9.23%) | 0.13% | $1 M | Nov 10, 2026 |
| 71 | Corient Private Wealth LP | 7,562 | +5,139 (+212.09%) | 0.13% | $1 M | Nov 16, 2026 |
| 72 | Monimus Capital Management, LP | 6,945 | -48,399 (-87.45%) | 0.12% | $1 M | Nov 16, 2026 |
| 73 | Jpmorgan Chase & Co | 6,868 | +2,919 (+73.92%) | 0.12% | $1 M | Nov 12, 2026 |
| 74 | Rhumbline Advisers | 6,674 | +114 (+1.74%) | 0.12% | $1 M | Nov 10, 2026 |
| 75 | Mariner, LLC | 6,559 | -7,848 (-54.47%) | 0.12% | $1 M | Nov 12, 2026 |
| 76 | Vident Advisory, LLC | 6,528 | -1,080 (-14.20%) | 0.12% | $1 M | Nov 16, 2026 |
| 77 | Alliancebernstein L.P. | 6,500 | 0 (0.00%) | 0.12% | $1 M | Nov 16, 2026 |
| 78 | Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 6,455 | New | 0.11% | $1 M | Oct 27, 2026 |
| 79 | Cerity Partners LLC | 5,940 | -1,473 (-19.87%) | 0.11% | $1 M | Nov 13, 2026 |
| 80 | CenterBook Partners LP | 5,756 | -1,983 (-25.62%) | 0.10% | $1 M | Nov 2, 2026 |
| 81 | LPL Financial LLC | 5,623 | -421 (-6.97%) | 0.10% | $1 M | Nov 6, 2026 |
| 82 | SEI Investments Co | 5,372 | -1,387 (-20.52%) | 0.10% | $1 M | Nov 10, 2026 |
| 83 | Mercer Global Advisors Inc /adv | 5,027 | -1,729 (-25.59%) | 0.09% | $1 M | Nov 16, 2026 |
| 84 | Thrivent Financial for Lutherans | 4,867 | New | 0.09% | $1 M | Nov 5, 2026 |
| 85 | Deutsche Bank AG\ | 4,728 | -652 (-12.12%) | 0.08% | $1 M | Nov 6, 2026 |
| 86 | Price T Rowe Associates Inc /MD/ | 4,393 | 0 (0.00%) | 0.08% | $1 M | Nov 16, 2026 |
| 87 | Citadel Advisors LLC | 4,278 | -31,612 (-88.08%) | 0.08% | $1 M | Nov 16, 2026 |
| 88 | Bank Of Nova Scotia | 4,091 | New | 0.07% | $1 M | Nov 13, 2026 |
| 89 | Gotham Asset Management, LLC | 4,070 | New | 0.07% | $1 M | Nov 16, 2026 |
| 90 | Quantbot Technologies LP | 3,891 | +3,827 (+5979.69%) | 0.07% | $1 M | Nov 12, 2026 |
| 91 | Boston Partners | 3,783 | -261,366 (-98.57%) | 0.07% | $0 M | Nov 10, 2026 |
| 92 | Keybank National Association/oh | 3,755 | New | 0.07% | $0 M | Nov 4, 2026 |
| 93 | Wealth Enhancement Advisory Services, LLC | 3,624 | -651 (-15.23%) | 0.06% | $0 M | Oct 13, 2026 |
| 94 | Vanguard Global Advisers, LLC | 3,330 | +1,338 (+67.17%) | 0.06% | $0 M | Nov 13, 2026 |
| 95 | Canada Pension Plan Investment Board | 3,300 | -3,000 (-47.62%) | 0.06% | $0 M | Nov 16, 2026 |
| 96 | Seizert Capital Partners, LLC | 3,227 | -219 (-6.36%) | 0.06% | $0 M | Oct 30, 2026 |
| 97 | MetLife Investment Management, LLC | 3,094 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 98 | Glenmede Trust Co NA | 3,010 | New | 0.05% | $0 M | Nov 16, 2026 |
| 99 | Prelude Capital Management, LLC | 2,984 | -157 (-5.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 100 | Caxton Associates LLP | 2,879 | New | 0.05% | $0 M | Nov 13, 2026 |
Mutual funds holding Mesa Laboratories, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 168,511 | $17 M | 3.0% | <0.01% | +2.6% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 138,875 | $14 M | 2.5% | 0.02% | +9.1% | Jun 30, 2026 |
| 🇺🇸 Diamond Hill Small Cap FundDiamond Hill Capital Management, Inc. | 109,454 | $11 M | 1.9% | 3.5% | −2.9% | Jun 30, 2026 |
| 🇺🇸 Column Small Cap Select FundTrust for Professional Managers | 87,923 | $9 M | 1.6% | 0.47% | +27% | May 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 74,048 | $7 M | 1.3% | 0.13% | +1353% | Jun 30, 2026 |
| 🇺🇸 Crawford Small Cap Dividend FundCrawford Investment Counsel Inc | 65,070 | $6 M | 1.2% | 1.7% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 62,568 | $6 M | 1.1% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Wasatch Micro Cap Value FundWasatch Advisors LP | 62,487 | $6 M | 1.1% | 1.6% | +160% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 58,440 | $6 M | 1.0% | 0.02% | +12% | Jul 31, 2026 |
| 🇺🇸 Keeley Gabelli Small Cap Dividend FundGabelli Funds, LLC | 53,974 | $5 M | 0.96% | 1.9% | no change | Jun 30, 2026 |
| 🇺🇸 Royce Small-Cap Trust, Inc.Royce & Associates, LP | 53,188 | $5 M | 0.95% | 0.20% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 50,244 | $5 M | 0.89% | 0.03% | +16% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 42,724 | $4 M | 0.76% | 0.04% | +4101% | Jun 30, 2026 |
| 🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP | 42,575 | $4 M | 0.76% | 0.47% | −36% | Jun 30, 2026 |
| 🇺🇸 WPG Partners Select Small Cap Value FundRBB Fund, Inc. | 34,829 | $4 M | 0.62% | 1.5% | +28% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 31,118 | $3 M | 0.55% | 0.32% | −19% | Jul 31, 2026 |
| 🇺🇸 Janus Henderson Small Cap Growth Alpha ETFJanus Henderson Investors US LLC | 30,109 | $3 M | 0.54% | 0.84% | +69% | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 28,769 | $3 M | 0.51% | <0.01% | −19% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 27,018 | $3 M | 0.48% | 0.02% | +3.4% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 26,518 | $3 M | 0.47% | 0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 WisdomTree U.S. SmallCap Dividend FundWisdomTree Asset Management, Inc. | 24,683 | $2 M | 0.44% | 0.11% | +1.7% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Targeted Value ETFDimensional Fund Advisors LP | 22,290 | $2 M | 0.40% | 0.02% | +38% | Jul 31, 2026 |
| 🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 21,544 | $2 M | 0.38% | 0.01% | +24% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 18,722 | $2 M | 0.33% | <0.01% | +7.0% | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 18,417 | $2 M | 0.33% | 0.02% | +4.0% | Jul 31, 2026 |
| 🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP | 17,948 | $2 M | 0.32% | 0.42% | −42% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 16,440 | $2 M | 0.29% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 15,672 | $2 M | 0.28% | 0.01% | −14% | Jul 31, 2026 |
| 🇺🇸 Virtus NFJ Small-Cap Value FundVirtus Investment Advisers, LLC | 13,169 | $1 M | 0.23% | 0.51% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 12,958 | $1 M | 0.23% | 0.02% | +12% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 13,092 | $1 M | 0.23% | 0.19% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 12,718 | $1 M | 0.23% | 0.05% | −0.1% | May 31, 2026 |
| 🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC | 12,920 | $1 M | 0.23% | 1.1% | — | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 11,543 | $1 M | 0.21% | <0.01% | +61% | Jul 31, 2026 |
| 🇺🇸 Principal U.S. Small-Cap ETFPrincipal Global Investors, LLC | 11,527 | $1 M | 0.21% | 0.05% | +7.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 10,085 | $1 M | 0.18% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 10,139 | $1 M | 0.18% | 0.02% | +14% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 9,814 | $1 M | 0.17% | 0.02% | +7.6% | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 8,763 | $1 M | 0.16% | 0.03% | −1.6% | Jul 31, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 8,657 | $1 M | 0.15% | 0.34% | +108% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,428 | $1 M | 0.15% | <0.01% | +4.6% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 8,137 | $1 M | 0.14% | 0.33% | −12% | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 7,490 | $1 M | 0.13% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 7,364 | $1 M | 0.13% | <0.01% | +3.8% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 7,149 | $1 M | 0.13% | 0.02% | +15% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 6,958 | $1 M | 0.12% | 0.07% | −11% | May 31, 2026 |
| 🇺🇸 Gabelli Dividend & Income TrustGabelli Funds, LLC | 7,100 | $1 M | 0.13% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 5,991 | $1 M | 0.11% | 0.02% | +14% | Jun 30, 2026 |
| 🇺🇸 WisdomTree U.S. SmallCap FundWisdomTree Asset Management, Inc. | 5,979 | $1 M | 0.11% | 0.08% | −2.6% | Jun 30, 2026 |
| 🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP | 5,915 | $1 M | 0.11% | 0.42% | — | Jun 30, 2026 |
| 🇺🇸 State Street Institutional Small-Cap Equity FundSSGA Funds Management, Inc. | 5,756 | $1 M | 0.10% | 0.11% | −4.6% | Jun 30, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 5,629 | $1 M | 0.10% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 5,500 | $1 M | 0.10% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Putnam Dynamic Asset Allocation Growth FundFranklin Advisers, Inc. | 5,486 | $1 M | 0.10% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Quality Factor ETFThe Vanguard Group, Inc. | 5,133 | $1 M | 0.09% | 0.11% | −0.4% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 4,907 | $1 M | 0.09% | 0.03% | +2.5% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 5,016 | $0 M | 0.09% | 0.03% | +26% | Jun 30, 2026 |
| 🇺🇸 Small Cap Dividend FundAmerican Century Investment Management, Inc. | 4,835 | $0 M | 0.09% | 0.44% | — | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 4,652 | $0 M | 0.08% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc. | 4,588 | $0 M | 0.08% | 0.07% | −38% | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 4,444 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Putnam Dynamic Asset Allocation Balanced FundFranklin Advisers, Inc. | 3,792 | $0 M | 0.07% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 3,607 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,500 | $0 M | 0.06% | 0.02% | +52% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 3,430 | $0 M | 0.06% | 0.02% | −5.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 3,105 | $0 M | 0.06% | <0.01% | +5.8% | May 31, 2026 |
| 🇺🇸 State Street SPDR US Small Cap Low Volatility Index ETFSSGA Funds Management, Inc. | 3,161 | $0 M | 0.06% | 0.12% | +16% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 3,066 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 3,003 | $0 M | 0.05% | <0.01% | +3.1% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 2,882 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 2,715 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 2,698 | $0 M | 0.05% | 0.02% | +18% | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 2,622 | $0 M | 0.05% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 2,558 | $0 M | 0.05% | 0.02% | +14% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 2,400 | $0 M | 0.04% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 2,040 | $0 M | 0.04% | <0.01% | +4.0% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 1,981 | $0 M | 0.04% | 0.01% | −12% | May 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,799 | $0 M | 0.03% | 0.02% | +17% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 1,798 | $0 M | 0.03% | <0.01% | −5.3% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 1,730 | $0 M | 0.03% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 1,639 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 1,599 | $0 M | 0.03% | <0.01% | +59% | Jul 31, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 1,549 | $0 M | 0.03% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 1,486 | $0 M | 0.03% | 0.02% | +17% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 1,481 | $0 M | 0.03% | 0.06% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP | 1,418 | $0 M | 0.03% | 0.02% | +6.9% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 1,407 | $0 M | 0.03% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 1,389 | $0 M | 0.02% | <0.01% | −1.0% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 1,269 | $0 M | 0.02% | 0.03% | −4.0% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,100 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 1,116 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 1,114 | $0 M | 0.02% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 1,099 | $0 M | 0.02% | 0.02% | +14% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 869 | $0 M | 0.02% | 0.02% | +3.9% | Jul 31, 2026 |
| 🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC | 873 | $0 M | 0.02% | 0.05% | +66% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 842 | $0 M | 0.01% | 0.02% | +13% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 808 | $0 M | 0.01% | 0.02% | +7.9% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 806 | $0 M | 0.01% | 0.02% | +17% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 769 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Growth PortfolioDimensional Fund Advisors LP | 714 | $0 M | 0.01% | <0.01% | +2.0% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Mesa Laboratories, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | John James SullivanDirector | Gift | -1,200 | — | — | 19,418 | Form 4 |
| filed | Shiraz Shabanali LadiwalaDirector | Option exercise | +3,810 | — | — | 12,333 | Form 4 |
| filed | Jennifer Sadie AlltoftDirector | Option exercise | +2,784 | — | — | 7,662 | Form 4 |
| filed | John James SullivanDirector | Option exercise | +2,784 | — | — | 20,618 | Form 4 |
| filed | R. Tony TripenyDirector | Option exercise | +2,784 | — | — | 9,082 | Form 4 |
| filed | Shannon HallDirector | Option exercise | +2,784 | — | — | 6,973 | Form 4 |
| filed | Mark Christopher CaponeDirector | Option exercise | +2,784 | — | — | 6,213 | Form 4 |
| filed | Siddhartha KadiaPresident and CEO | Buyindirect | +7,093 | $112.80 | $800 K | 7,093 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Ownership and subsidiaries
- MESA FRANCE🇫🇷 CHASSIEU
Markets and events: Mesa Laboratories, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
| Dividend, quarter | Per share | |
|---|---|---|
| Q3 2026 | $0.160 | |
| Q2 2026 | $0.160 | |
| Q1 2026 | $0.160 | from the annual figure |
| Q4 2025 | $0.160 | |
| Q3 2025 | $0.160 | |
| Q2 2025 | $0.160 | |
| Q1 2025 | $0.160 | from the annual figure |
| Q4 2024 | $0.160 | |
| Q3 2024 | $0.160 | |
| Q2 2024 | $0.160 | |
| Q1 2024 | $0.160 | from the annual figure |
| Q4 2023 | $0.160 | |
| Q3 2023 | $0.160 | |
| Q2 2023 | $0.160 | |
| Q1 2023 | $0.160 | from the annual figure |
| Q4 2022 | $0.160 | |
| Q3 2022 | $0.160 | |
| Q2 2022 | $0.160 | |
| Q1 2022 | $0.160 | from the annual figure |
| Q4 2021 | $0.160 | |
| Q3 2021 | $0.160 | |
| Q2 2021 | $0.160 | |
| Q1 2021 | $0.160 | from the annual figure |
| Q4 2020 | $0.160 | |
| Q3 2020 | $0.160 | |
| Q2 2020 | $0.160 | |
| Q4 2019 | $0.640 | |
| Q3 2019 | $0.160 | |
| Q2 2019 | $0.160 | |
| Q1 2013 | $0.140 | |
| Q4 2012 | $0.140 | |
| Q3 2012 | $0.130 | |
| Q2 2012 | $0.130 | |
| Q1 2012 | $0.130 | |
| Q4 2011 | $0.130 | |
| Q3 2011 | $0.120 | |
| Q2 2011 | $0.120 | |
| Q1 2011 | $0.120 | |
| Q4 2010 | $0.120 | |
| Q3 2010 | $0.110 |
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2014 | Q4 2014 | $0M |
| Q4 2013 | Q3 2013 | $0M |
| Q3 2013 | Q2 2013 | $0M |
| Q2 2013 | Q1 2013 | $0M |
| Q1 2013 | Q4 2012 | $0M |
| Q4 2012 | Q3 2012 | $0M |
| Q3 2012 | Q2 2012 | $0M |
| Q2 2012 | Q1 2012 | $0M |
| Q1 2012 | Q4 2011 | $0.5M |
| Q3 2011 | Q2 2011 | $0.1M |
| Q2 2011 | Q1 2011 | $0M |
| Q1 2011 | Q4 2011 | $0M |
| Q4 2010 | Q3 2011 | $0M |
| Q3 2010 | Q2 2011 | $0.1M |
| Q2 2010 | Q1 2011 | $0M |
Fails to deliver
- : 336 shares at $129.25
- : 173 shares at $123.31
- : 246 shares at $133.01
- : 11 shares at $127.14
- : 5,200 shares at $130.65
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Mesa Laboratories, Inc. scorecard#
Passes 16 of the 29 checks that could be worked out: strongest in growth (5 of 6), weakest in valuation (2 of 6). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation2 of 6
- ✗P/E below its peers' median109.1×P/E 109.1× against Scientific Technical Instruments's median of 32.5×.
- ✗Price to book below its peers' median3.9×Price to book 3.9× against Scientific Technical Instruments's median of 3.8×.
- ✓Price to sales below its peers' median2.9×Price to sales 2.9× against Scientific Technical Instruments's median of 4.7×.
- ✓Free cash flow yield above 5%5.5%Free cash flow is 5.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yield0.9%Earnings yield 0.9% against the 10-year Treasury's 5.15% on 2026-11-13.
- ✗The price assumes slower growth than the last three years'7.0%The price assumes 7.0% a year for ten years; revenue grew 4.4% a year over the last three.
Growth5 of 6
- ✓Revenue grew in the newest year3.4%Revenue up 3.4% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years4.4%4.4% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median4.4%4.4% a year against Scientific Technical Instruments's median of 3.0% (24 companies).
- ✓Earnings per share grew in the newest year1.21 vs -0.36Diluted EPS 1.21 in fiscal 2025 against -0.36 the year before (report's currency).
- ✓Net income higher than five years earlier$7 M$7 M in fiscal 2025 against $3 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability2 of 6
- ✓Profitable in the newest year$7 MNet income $7 M in fiscal 2025.
- ✗Profitable in each of the last five years3 of 5Profitable in 3 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median7.4%7.4% against Scientific Technical Instruments's median of 9.1% (26 companies).
- ✗Return on equity above 15%3.9%3.9% in fiscal 2025.
- ✗Return on invested capital above 10%4.8%4.8% in fiscal 2025.
- ✓Operating margin wider than three years earlier7.4%7.4% in fiscal 2025 against 1.5% in 2022.
Financial health4 of 5
- ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.72 at the end of fiscal 2025.
- ✓Debt below equity0.4×Debt to equity 0.36 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times1.7×Operating income 1.7 times interest in fiscal 2025.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone2.05Z-score 2.05 (grey zone) for fiscal 2025.
Shareholder returns3 of 6
- ✓Pays a dividendYesPaid dividends in fiscal 2025.
- ✗Dividend per share raised five years in a row0 of 5Dividend per share raised in 0 of the five years to fiscal 2025.
- ✓Dividends under 75% of net income52.5%Dividends were 52.5% of net income in fiscal 2025.
- ✗Share count up no more than 2% in a year2.7%Diluted shares up 2.7% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.5%Dividends and buybacks were 0.5% of the market value.
- ✓Free cash flow covers dividends and buybacks$40 MFree cash flow $40 M against $4 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Scientific Technical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Mesa Laboratories, Inc.'s statements, beside the median of Scientific Technical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 7.4% | 9.1% | |
| Net margin | 2.7% | 8.7% | |
| Return on equity | 3.9% | 3.9% | |
| Revenue growth, 3 years a year | 4.4% | 3.0% | |
| Revenue growth | 3.4% | 4.0% | |
| Debt to equity | 0.36× | 0.32× |
8of 9on the Piotroski tests of financial strength
- Operating income covers the interest bill only 1.7 times.
- Goodwill and intangibles ($270 million) exceed shareholders' equity ($186 million).
- Free cash flow has been positive 9 years in a row.
Mesa Laboratories, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Mar 31, 2026 | FY 2024to Mar 31, 2025 | FY 2023to Mar 31, 2024 | FY 2022to Mar 31, 2023 | FY 2021to Mar 31, 2022 | FY 2020to Mar 31, 2021 | FY 2019to Mar 31, 2020 | FY 2018to Mar 31, 2019 | FY 2017to Mar 31, 2018 | FY 2016to Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 249+3.4%100% | 241+11.5%100% | 216−1.3%100% | 219+18.8%100% | 184+37.6%100% | 134+13.8%100% | 118+14.1%100% | 103+7.2%100% | 96+2.7%100% | 94—100% | |
| Cost of revenue | 91+0.8%36.5% | 90+8.6%37.4% | 83−2.9%38.4% | 85+13.5%39.0% | 75+60.4%40.8% | 47−10.3%35.0% | 52r53+23.9%44.5% | 42+1.6%40.9% | 42+2.8%43.2% | 40—43.2% | |
| Gross profit | 158+4.9%63.5% | 151+13.2%62.6% | 133−0.3%61.6% | 134+22.6%61.0% | 109+25.4%59.2% | 87+33.1%65.0% | 65r65+7.3%55.5% | 61+11.5%59.1% | 55+2.6%56.8% | 53—56.8% | |
| Research and development | 20+4.0%8.2% | 20+1.1%8.1% | 19−5.8%8.9% | 20+30.0%9.4% | 16+51.8%8.6% | 10+63.5%7.8% | 6.4+81.3%5.4% | 3.5−0.9%3.4% | 3.5−14.9%3.7% | 4.2—4.4% | |
| Selling and marketing | 41−2.1%16.4% | 42+7.9%17.3% | 39+3.2%17.9% | 37+32.2%17.1% | 28+53.2%15.4% | 18+43.1%13.8% | 13+56.3%11.0% | 8.3−6.4%8.0% | 8.8−11.4%9.2% | 10.0—10.6% | |
| General and administrative | 79+7.3%31.6% | 73+0.6%30.4% | 73+0.6%33.7% | 72+20.1%33.1% | 60+31.7%32.7% | 46r46+19.9%34.2% | 38r38+22.0%32.4% | 31+19.2%30.3% | 26+15.1%27.3% | 23—24.4% | |
| Operating expenses | 140+3.9%56.1% | 135−66.8%55.8% | 405+211%187% | 130+24.9%59.5% | 104+39.8%56.6% | 75+30.0%55.7% | 57+12.3%48.8% | 51−2.5%49.6% | 52+42.0%54.5% | 37—39.4% | |
| Operating income | 19+13.3%7.4% | 16—6.8% | −272−8295%−126% | 3.3−29.4%1.5% | 4.7−62.0%2.6% | 12+56.0%9.2% | 7.9r7.5−19.0%6.7% | 9.8+348%9.5% | 2.2−86.6%2.3% | 16—17.4% | |
| Interest and finance income | — | — | — | — | — | 0.1−88.9%0.1% | 1.0+3210%0.8% | 0.0+480%0.0% | 0.0—0.0% | — | |
| Interest expense and finance costs | 11−9.8%4.3% | 12+108%4.9% | 5.7+19.4%2.6% | 4.8+22.8%2.2% | 3.9−51.6%2.1% | 8.0+45.8%6.0% | 5.5+215%4.7% | 1.7−5.6%1.7% | 1.9—1.9% | — | |
| Other non-operating income (expense) | −6.5—−2.6% | −10—−4.3% | −3.6—−1.7% | −3.7—−1.7% | −1.1—−0.6% | −10—−7.5% | −4.1—−3.5% | −1.2—−1.1% | −1.9—−2.0% | −2.0—−2.2% | |
| Income before tax | 12+102%4.8% | 6.0—2.5% | −276—−128% | −0.4−111%−0.2% | 3.6+55.2%1.9% | 2.3−40.4%1.7% | 3.9r3.4−55.2%3.3% | 8.6+2765%8.4% | 0.3−97.9%0.3% | 14—15.3% | |
| Income tax | 5.3−33.2%2.1% | 7.9—3.3% | −21—−9.9% | −1.3−177%−0.6% | 1.7—0.9% | −1.0−147%−0.7% | 2.1+83.0%1.8% | 1.1−65.1%1.1% | 3.3+4.8%3.4% | 3.1—3.3% | |
| Income from continuing operations | 12+102%4.8% | 6.0—2.5% | −276—−128% | −0.4—−0.2% | — | — | — | — | — | — | |
| Net income attributable to shareholders | 6.7—2.7% | −2.0—−0.8% | −254−27438%−118% | 0.9−50.3%0.4% | 1.9−42.9%1.0% | 3.3—2.4% | — | — | — | — | |
| Earnings per share, basic | 1.22—— | -0.36—— | -47.20−27865%— | 0.17−52.8%— | 0.36−45.5%— | 0.66+57.1%— | 0.42r0.32−78.5%— | 1.95—— | -0.79−126%— | 3.04—— | |
| Earnings per share, diluted | 1.21—— | -0.36—— | -47.20−27865%— | 0.17−51.4%— | 0.35−45.3%— | 0.64+56.1%— | 0.41r0.31−78.0%— | 1.86—— | -0.79−127%— | 2.91—— | |
| Shares, weighted average (basic) | 5.5+1.7%— | 5.4+0.6%— | 5.4+1.2%— | 5.3+2.1%— | 5.2+4.8%— | 5.0+18.5%— | 4.2+9.4%— | 3.8+1.8%— | 3.8+2.5%— | 3.7—— | |
| Shares, weighted average (diluted) | 5.6+2.7%— | 5.4+0.6%— | 5.4+0.5%— | 5.4+0.5%— | 5.3+4.1%— | 5.1+17.2%— | 4.4+8.4%— | 4.0+7.0%— | 3.8−1.9%— | 3.8—— | |
| Dividends per share | 0.640.0%— | 0.640.0%— | 0.640.0%— | 0.640.0%— | 0.640.0%— | 0.640.0%— | 0.640.0%— | 0.64—— | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 27−1.4%6.3% | 27−3.2%6.3% | 28−14.3%6.3% | 33−33.3%5.0% | 49−81.3%7.0% | 264+224%43.9% | 81+699%19.9% | 10+86.2%6.5% | 5.5−6.0%3.3% | 5.8—3.4% | |
| Receivables | 44+5.1%10.3% | 42+7.5%9.7% | 39−8.2%8.7% | 43+3.2%6.4% | 41+73.3%5.8% | 24+12.6%4.0% | 21+68.8%5.2% | 13−12.5%8.0% | 14−0.1%8.7% | 14—8.3% | |
| Inventory | 26+4.0%6.2% | 25−22.4%5.9% | 33−5.7%7.3% | 35+40.8%5.2% | 25+120%3.5% | 110.0%1.9% | 11r14+65.1%2.7% | 6.8−26.6%4.3% | 9.2−33.5%5.6% | 14—8.1% | |
| Other current assets | 3.6+26.0%0.8% | 2.9−14.0%0.7% | 3.3−17.4%0.7% | 4.0r8.9+74.0%0.6% | 2.3r3.7−52.7%0.3% | 4.9r0.8+157%0.8% | 1.9r4.1+19.8%0.5% | 1.6+104%1.0% | 0.8−34.1%0.5% | 1.2r1.8—0.7% | |
| Current assets | 106+3.5%24.8% | 103−6.1%23.7% | 109−8.1%24.5% | 119−4.3%18.0% | 124−59.1%17.6% | 304+147%50.5% | 123+265%30.0% | 34+5.1%21.4% | 32−10.6%19.5% | 36—20.8% | |
| Property, plant and equipment | 31−5.3%7.2% | 32+1.8%7.5% | 32+12.8%7.1% | 28−1.6%4.3% | 29+30.1%4.0% | 22−0.3%3.7% | 22−0.7%5.4% | 22−5.8%14.2% | 24−9.3%14.4% | 26—15.1% | |
| Right-of-use (leased) assets | 18+6.8%4.1% | 16+69.4%3.8% | 9.7+11.3%2.2% | 8.7—1.3% | — | — | — | — | — | — | |
| Goodwill | 187+2.8%43.7% | 182+0.9%41.9% | 180−37.1%40.3% | 286−1.6%43.3% | 291+81.0%41.2% | 161+13.6%26.7% | 142+113%34.6% | 66+1.3%42.3% | 66−9.2%39.9% | 72—42.0% | |
| Other intangible assets | 83−14.0%19.5% | 97−14.8%22.4% | 114−47.5%25.5% | 217−13.3%32.8% | 250+124%35.4% | 112−6.8%18.6% | 120+261%29.3% | 33−22.5%21.2% | 43+13.4%26.1% | 38—22.0% | |
| Total assets | 428−1.3%100% | 433−3.0%100% | 447−32.5%100% | 662−6.4%100% | 707+17.6%100% | 601+47.0%100% | 409r420+161%100% | 157−4.5%100% | 164−4.4%100% | 172—100% | |
| Accounts payable | 4.9−14.3%1.2% | 5.7−4.9%1.3% | 6.0−1.5%1.4% | 6.1−22.3%0.9% | 7.9+76.5%1.1% | 4.5+31.3%0.7% | 3.4+17.6%0.8% | 2.9+21.8%1.8% | 2.4+9.8%1.5% | 2.2—1.3% | |
| Debt due within a year | — | — | — | — | — | — | — | 2.1+30.8%1.4% | 1.6+44.4%1.0% | 1.1—0.7% | |
| Current liabilities | 62−62.2%14.5% | 164+270%37.8% | 44+2.2%9.9% | 43−9.8%6.6% | 48+47.5%6.8% | 33+25.3%5.4% | 26+9.9%6.4% | 24+36.8%15.1% | 17+4.4%10.5% | 17—9.6% | |
| Long-term debt | — | — | — | — | — | — | — | 21−53.8%13.1% | 45−16.8%27.2% | 54—31.3% | |
| Lease liabilities (non-current) | 14+10.4%3.2% | 12+87.2%2.9% | 6.6+15.0%1.5% | 5.8—0.9% | — | — | — | — | — | — | |
| Total liabilities | 242−11.7%56.5% | 274−9.3%63.1% | 301+12.3%67.5% | 268−14.4%40.5% | 314+60.6%44.3% | 195+3.3%32.5% | 189r200+316%46.2% | 45−29.8%29.0% | 65−12.4%39.5% | 74—43.0% | |
| Retained earnings | −186—−43.4% | −189—−43.6% | −183−347%−41.1% | 74−3.2%11.2% | 77+5.8%10.8% | 72+0.1%12.0% | 72r72−1.3%17.7% | 73+7.4%46.8% | 68−7.3%41.6% | 74—42.9% | |
| Shareholders' equity | 186+16.5%43.5% | 160+9.9%36.9% | 145−63.0%32.5% | 393−0.1%59.5% | 394−3.1%55.7% | 406+84.6%67.5% | 220+97.7%53.8% | 111+12.0%71.0% | 99+1.6%60.5% | 98—57.0% | |
| Total liabilities and equity | 428−1.3%100% | 433−3.0%100% | 447−32.5%100% | 662−6.4%100% | 707+17.6%100% | 601+47.0%100% | 409r420+161%100% | 157−4.5%100% | 164−4.4%100% | 172—100% | |
| Shares outstanding | 5.5+1.3%— | 5.5+1.1%— | 5.4+0.5%— | 5.4+2.0%— | 5.3+2.4%— | 5.1+17.2%— | 4.4+12.8%— | 3.9+2.3%— | 3.8+1.8%— | 3.7r3.7—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | 34+34.9%15.4% | 25+41.9%13.6% | 18+36.0%13.2% | 13+37.8%11.0% | 9.4−0.5%9.1% | 9.5+8.4%9.8% | 8.7—9.3% | |
| Share-based compensation | 18+36.0%7.2% | 13+10.1%5.5% | 12−4.8%5.5% | 13+10.1%5.7% | 11+22.9%6.2% | 9.3+67.7%6.9% | 5.5+31.2%4.7% | 4.2+152%4.1% | 1.7+18.5%1.7% | 1.4—1.5% | |
| Cash from operating activities | 43−8.5%17.2% | 47+6.1%19.4% | 44+57.7%20.4% | 28−28.7%12.8% | 39+5.8%21.3% | 37+37.4%27.7% | 27r27−11.7%22.9% | 31+18.8%29.6% | 26r25+48.6%26.7% | 17r7.8—18.5% | |
| Capital expenditure | −3.3—−1.3% | −4.2—−1.8% | −2.6—−1.2% | −4.5—−2.1% | −4.4—−2.4% | −2.0—−1.5% | −1.5—−1.3% | −1.3—−1.2% | −2.8—−2.9% | — | |
| Intangible assets bought | 0—0.0% | −0.3—−0.1% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | |
| Acquisitions, net of cash acquired | 0—0.0% | 0—0.0% | −79—−36.4% | −5.0—−2.3% | −301—−163% | 0—0.0% | −184—−156% | −4.8—−4.7% | −16—−16.1% | −8.6—−9.2% | |
| Cash from investing activities | −3.3—−1.3% | −4.5—−1.9% | −81—−37.6% | −9.5—−4.3% | −305—−166% | −2.0—−1.5% | −186—−158% | −3.9—−3.8% | −17—−17.9% | −18—−19.6% | |
| Debt repaid | −37—−14.8% | −44—−18.4% | −34—−15.5% | −36—−16.4% | −21—−11.4% | 0—0.0% | −23—−19.5% | −26—−24.8% | −20—−20.4% | −57—−60.9% | |
| Shares issued | — | — | — | 0—0.0% | 0−100%0.0% | 146+71.7%109% | 85—72.2% | 0—0.0% | — | — | |
| Dividends paid | −3.5—−1.4% | −3.5—−1.4% | −3.4—−1.6% | −3.4—−1.6% | −3.3—−1.8% | −3.2—−2.4% | −2.7—−2.3% | −2.5—−2.4% | −2.4—−2.5% | −2.4—−2.5% | |
| Cash from financing activities | −42—−16.8% | −45−236%−18.5% | 33—15.2% | −33−163%−15.2% | 53−64.0%28.5% | 146−36.8%109% | 231—197% | −22—−21.0% | −9.0r−8.1−882%−9.4% | 1.2r11—1.2% | |
| Change in cash | −0.4—−0.2% | −0.9—−0.4% | −4.7—−2.2% | −16—−7.5% | −215−218%−116% | 182+156%136% | 71+1410%60.5% | 4.7—4.6% | −0.4−381%−0.4% | 0.1—0.1% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q2 FY2026to Sep 30, 2026 | Q1 FY2026to Jun 30, 2026 | Q4 FY2025to Mar 31, 2026 | Q3 FY2025to Dec 31, 2025 | Q2 FY2025to Sep 30, 2025 | Q1 FY2025to Jun 30, 2025 | Q4 FY2024to Mar 31, 2025 | Q3 FY2024to Dec 31, 2024 | Q2 FY2024to Sep 30, 2024 | Q1 FY2024to Jun 30, 2024 | Q4 FY2023to Mar 31, 2024 | Q3 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 251+2.5%100% | 62+2.6%100% | 60+1.0%100% | 64*+2.6%100% | 65+3.6%100% | 61+5.0%100% | 60+2.4%100% | 62*+5.5%100% | 63+17.5%100% | 58—100% | 58—100% | 59*—100% | 53—100% | |
| Cost of revenue | 88−4.7%35.2% | 22−4.1%36.0% | 21−6.5%35.1% | 22*−9.3%33.8% | 23+1.1%35.8% | 23+4.6%38.5% | 23+8.0%38.0% | 24*+6.2%38.2% | 23+15.0%36.7% | 22—38.7% | 21—36.0% | 22*—37.9% | 20—37.5% | |
| Gross profit | 163+6.9%64.8% | 40+6.8%64.0% | 39+5.6%64.9% | 42*+9.9%66.2% | 42+5.1%64.2% | 37+5.3%61.5% | 37−0.8%62.0% | 38*+5.1%61.8% | 40+19.0%63.3% | 35—61.3% | 37—64.0% | 37*—62.1% | 33—62.5% | |
| Research and development | 20−0.6%8.0% | 5.1+0.1%8.1% | 4.7−5.2%7.9% | 5.2*+3.0%8.2% | 5.0−0.5%7.7% | 5.0+8.9%8.3% | 5.0+5.3%8.4% | 5.1*−2.0%8.2% | 5.1+17.7%8.0% | 4.6—8.0% | 4.7—8.1% | 5.2*—8.8% | 4.3—8.0% | |
| Selling and marketing | 40−6.3%15.8% | 9.8+0.3%15.8% | 9.9−9.7%16.4% | 10*−10.6%15.8% | 10.0−4.4%15.3% | 9.8−0.5%16.1% | 11+8.1%18.4% | 11*+9.8%18.1% | 10+7.3%16.6% | 9.8—17.0% | 10—17.4% | 10*—17.4% | 9.7—18.2% | |
| General and administrative | 77+2.9%30.6% | 17−6.5%26.7% | 17−3.2%28.9% | 24*+17.3%37.9% | 19+1.8%28.9% | 18+1.7%29.2% | 18+6.8%30.2% | 21*+15.3%33.1% | 18−5.0%29.4% | 17—30.2% | 17—28.9% | 18*—30.3% | 19—36.4% | |
| Operating expenses | 137−0.5%54.4% | 31−3.4%50.5% | 32−5.6%53.2% | 39*+6.8%61.9% | 34−0.5%51.9% | 33+2.1%53.7% | 34+7.0%56.9% | 37*−88.0%59.5% | 34+1.5%54.1% | 32—55.2% | 32—54.4% | 308*—523% | 33—62.6% | |
| Operating income | 26+73.9%10.4% | 8.4+77.6%13.5% | 7.0+129%11.7% | 2.7*+87.1%4.3% | 8.0+38.0%12.2% | 4.7+34.7%7.8% | 3.1−45.1%5.1% | 1.5*—2.4% | 5.8—9.2% | 3.5—6.1% | 5.6—9.6% | −271*—−461% | −0.1—−0.1% | |
| Interest expense and finance costs | 10−2.8%4.0% | 2.1−25.3%3.4% | 2.4+7.5%3.9% | 2.6*+3.1%4.1% | 3.0+6.8%4.7% | 2.9−5.2%4.7% | 2.2−22.7%3.7% | 2.5*+33.4%4.1% | 2.8+53.1%4.5% | 3.0—5.2% | 2.8—4.9% | 1.9*—3.2% | 1.9—3.5% | |
| Other non-operating income (expense) | −13—−5.1% | −2.4—−3.8% | −2.7−168%−4.5% | −4.3*—−6.8% | −3.4—−5.2% | −2.7−996%−4.5% | 3.9—6.6% | −1.0*—−1.6% | −8.0−497%−12.7% | 0.3—0.5% | −1.7—−2.9% | −4.0*—−6.9% | 2.0—3.8% | |
| Income before tax | 13+84.6%5.3% | 6.0+202%9.7% | 4.4−37.9%7.2% | −1.6*−446%−2.5% | 4.6—7.1% | 2.0−47.6%3.3% | 7.0+79.6%11.8% | 0.5*—0.7% | −2.2−214%−3.5% | 3.8—6.6% | 3.9—6.7% | −275*—−467% | 1.9—3.6% | |
| Income tax | 6.7−23.8%2.7% | 1.7—2.7% | 1.5−32.9%2.5% | 2.5*−66.4%4.0% | 1.0—1.5% | −0.5−224%−0.8% | 2.3+339%3.8% | 7.6*—12.2% | −0.5—−0.9% | 0.4—0.7% | 0.5—0.9% | −21*—−35.2% | −0.2—−0.3% | |
| Net income attributable to shareholders | 6.7—2.7% | 4.3+75.3%7.0% | 2.8−40.3%4.7% | −4.1*—−6.5% | 3.6—5.6% | 2.5−27.8%4.1% | 4.7+40.0%8.0% | −7.1*—−11.4% | −1.7−179%−2.7% | 3.4—5.9% | 3.4—5.8% | −255*—−432% | 2.1—4.0% | |
| Earnings per share, basic | — | 0.77+71.1%— | 0.50−42.5%— | — | 0.66—— | 0.45−28.6%— | 0.87+38.1%— | — | -0.31−179%— | 0.63—— | 0.63—— | — | 0.39—— | |
| Earnings per share, diluted | — | 0.75+66.7%— | 0.49−42.4%— | — | 0.65—— | 0.45−28.6%— | 0.85+37.1%— | — | -0.31−179%— | 0.63—— | 0.62—— | — | 0.39—— | |
| Shares, weighted average (basic) | 5.6+2.4%— | 5.6+2.4%— | 5.7+3.5%— | — | 5.5+1.9%— | 5.5+1.8%— | 5.5+1.3%— | — | 5.4+0.7%— | 5.4—— | 5.4—— | — | 5.4—— | |
| Shares, weighted average (diluted) | 5.8+4.1%— | 5.8+4.1%— | 5.8+3.7%— | — | 5.6+2.5%— | 5.5+1.2%— | 5.6+2.4%— | — | 5.4+0.6%— | 5.5—— | 5.4—— | — | 5.4—— | |
| Dividends per share | — | 0.160.0%— | 0.160.0%— | — | 0.160.0%— | 0.160.0%— | 0.160.0%— | — | 0.160.0%— | 0.16—— | 0.16—— | — | 0.16—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 22—5.5% | 22+9.3%5.5% | 31+44.3%7.3% | 27−1.4%6.3% | 29+6.1%6.7% | 20−16.1%4.7% | 21−25.3%4.9% | 27−3.2%6.3% | 27r31−3.2%6.3% | 24—5.4% | 28—6.5% | 28—6.3% | 28—3.8% | |
| Receivables | 39—9.7% | 39−1.8%9.7% | 34−11.9%8.2% | 44+5.1%10.3% | 40−4.1%9.3% | 40−0.4%9.3% | 39+9.8%9.0% | 42+7.5%9.7% | 42r39+16.5%9.7% | 40—8.9% | 36—8.1% | 39—8.7% | 36—4.9% | |
| Inventory | 27—6.5% | 27−4.3%6.5% | 27−3.1%6.5% | 26+4.0%6.2% | 27+4.7%6.1% | 28−6.7%6.4% | 28−11.5%6.5% | 25−22.4%5.9% | 25r28−29.5%5.9% | 30—6.5% | 32—7.2% | 33—7.3% | 36—4.8% | |
| Other current assets | 4.9—1.2% | 4.9+35.7%1.2% | 4.5+35.5%1.1% | 3.6+26.0%0.8% | 3.9+38.1%0.9% | 3.6−8.4%0.8% | 3.3−9.3%0.8% | 2.9−14.0%0.7% | 2.8−37.3%0.7% | 3.9—0.9% | 3.6—0.8% | 3.3—0.7% | 4.5—0.6% | |
| Current assets | 98—24.1% | 98+0.8%24.1% | 103+4.7%24.5% | 106+3.5%24.8% | 106+2.9%24.3% | 97−9.8%22.6% | 98−7.9%22.5% | 103−6.1%23.7% | 103r111−13.2%23.7% | 108—23.8% | 107—24.2% | 109—24.5% | 118—16.0% | |
| Property, plant and equipment | 29—7.2% | 29−7.8%7.2% | 30−5.1%7.2% | 31−5.3%7.2% | 32−2.3%7.3% | 32−0.7%7.4% | 32+0.9%7.3% | 32+1.8%7.5% | 32r32+1.8%7.5% | 32—7.1% | 31—7.1% | 32—7.1% | 32—4.3% | |
| Right-of-use (leased) assets | — | — | — | 18+6.8%4.1% | — | — | — | 16+69.4%3.8% | — | — | — | 9.7—2.2% | — | |
| Goodwill | 185—45.4% | 185−1.7%45.4% | 187r186−0.6%44.6% | 187+2.8%43.7% | 189+4.1%43.5% | 188+2.6%43.8% | 188+4.6%43.2% | 182+0.9%41.9% | 182r177−47.5%41.9% | 184—40.5% | 180—40.8% | 180—40.3% | 346—46.7% | |
| Other intangible assets | 74—18.0% | 74−21.2%18.0% | 78−19.5%18.7% | 83−14.0%19.5% | 90−8.7%20.6% | 93−14.3%21.7% | 97−11.0%22.4% | 97−14.8%22.4% | 98−57.8%22.7% | 109—24.0% | 109—24.9% | 114—25.5% | 233—31.4% | |
| Total assets | 408—100% | 408−5.3%100% | 419−3.8%100% | 428−1.3%100% | 435+0.3%100% | 430−5.2%100% | 436−1.0%100% | 433−3.0%100% | 433r437−41.6%100% | 454—100% | 440—100% | 447—100% | 742—100% | |
| Accounts payable | 4.8—1.2% | 4.8−5.3%1.2% | 7.5+19.0%1.8% | 4.9−14.3%1.2% | 5.3−8.6%1.2% | 5.1−15.0%1.2% | 6.3+10.8%1.4% | 5.7−4.9%1.3% | 5.7r4.1+26.2%1.3% | 6.0—1.3% | 5.7—1.3% | 6.0—1.4% | 4.6—0.6% | |
| Current liabilities | 52—12.7% | 52+6.8%12.7% | 57−61.7%13.7% | 62−62.2%14.5% | 54−66.8%12.5% | 48−68.5%11.2% | 149+172%34.3% | 164+270%37.8% | 164r156+271%37.8% | 153—33.7% | 55—12.5% | 44—9.9% | 44—6.0% | |
| Lease liabilities (non-current) | 16—3.9% | 16—3.9% | 16—3.8% | 14+10.4%3.2% | — | — | — | 12+87.2%2.9% | — | — | — | 6.6—1.5% | — | |
| Total liabilities | 213—52.3% | 213−15.4%52.3% | 230−12.5%55.0% | 242−11.7%56.5% | 248−9.3%57.1% | 252−13.9%58.5% | 263−9.1%60.4% | 274−9.3%63.1% | 274r282−19.3%63.1% | 293—64.4% | 290—65.8% | 301—67.5% | 339—45.7% | |
| Retained earnings | −180—−44.2% | −180—−44.2% | −184—−43.8% | −186—−43.4% | −181—−41.6% | −183—−42.6% | −185—−42.5% | −189—−43.6% | −189r−181−363%−43.6% | −178—−39.3% | −181—−41.1% | −183—−41.1% | 72—9.7% | |
| Shareholders' equity | 195—47.7% | 195+9.0%47.7% | 189+9.4%45.0% | 186+16.5%43.5% | 187+20.3%42.9% | 178+10.5%41.5% | 172+14.4%39.6% | 160+9.9%36.9% | 155r155−61.5%35.8% | 161—35.6% | 151—34.2% | 145—32.5% | 403—54.3% | |
| Total liabilities and equity | 408—100% | 408−5.3%100% | 419−3.8%100% | 428−1.3%100% | 435+0.3%100% | 430−5.2%100% | 436−1.0%100% | 433−3.0%100% | 433r437−41.6%100% | 454—100% | 440—100% | 447—100% | 742—100% | |
| Shares outstanding | 5.6—— | 5.6+1.9%— | 5.6+1.7%— | 5.5+1.3%— | 5.5+1.3%— | 5.5+1.7%— | 5.5+1.7%— | 5.5+1.1%— | 5.5r5.4+1.1%— | 5.4—— | 5.4—— | 5.4—— | 5.4—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 16+13.1%6.3% | 3.4*−11.4%5.4% | 2.4−39.2%3.9% | 6.8*+116%10.7% | 3.4*+4.4%5.2% | 3.8*−0.7%6.3% | 3.9+32.5%6.5% | 3.1*+12.4%5.1% | 3.2*+8.2%5.2% | 3.8*—6.6% | 2.9—5.0% | 2.8*—4.7% | 3.0—5.6% | |
| Cash from operating activities | 52+26.0%20.5% | 4.1*−50.2%6.6% | 15+678%24.5% | 14*+10.2%21.9% | 19*+3.4%28.8% | 8.2*+56.0%13.5% | 1.9−82.4%3.2% | 13*−1.7%20.4% | 18r18*+57.2%28.8% | 5.3r5.3*—9.1% | 11r10—18.5% | 13*—21.9% | 12*—21.6% | |
| Capital expenditure | −2.1—−0.8% | −0.4*—−0.6% | −0.6—−0.9% | −0.4*—−0.7% | −0.7*—−1.1% | −1.1*—−1.8% | −1.0—−1.7% | −0.8*—−1.2% | −0.8*—−1.3% | −1.8*—−3.1% | −0.9—−1.5% | −0.5*—−0.9% | −1.1*—−2.1% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | 0*—0.0% | — | — | — | — | — | |
| Cash from investing activities | −2.1—−0.8% | −0.4*—−0.6% | −0.6—−0.9% | −0.4*—−0.7% | −0.7*—−1.1% | −1.1*—−1.8% | −1.0—−1.7% | −1.0*−336%−1.6% | −0.8*—−1.3% | −1.8*—−3.1% | −0.9—−1.5% | 0.4*—0.7% | −81*—−151% | |
| Debt repaid | — | −11*—−18.3% | −19—−31.0% | −15*—−23.0% | — | −103r−5.9*—−170% | −7.4—−12.5% | −18*—−28.9% | −9.4*—−15.0% | −7.4*—−12.9% | −9.4—−16.2% | −12*—−19.5% | −9.0*—−16.8% | |
| Dividends paid | −3.6—−1.4% | −0.9*—−1.4% | −0.9—−1.5% | −0.9*—−1.4% | −0.9*—−1.4% | −0.9*—−1.5% | −0.9—−1.5% | −0.9*—−1.4% | −0.9*—−1.4% | −0.9*—−1.5% | −0.9—−1.5% | −0.9*—−1.5% | −0.9*—−1.6% | |
| Cash from financing activities | −48—−19.2% | −12*—−19.8% | −10—−17.5% | −16*—−24.7% | −9.8*—−15.0% | −7.9*—−13.0% | −8.4—−14.2% | −16*—−26.1% | −10r−11*−117%−16.4% | −8.6r−8.6*—−14.9% | −9.4r−9.1—−16.2% | −13*—−22.0% | 61*—114% | |
| Change in cash | 1.9—0.8% | −8.4*—−13.4% | 3.8—6.3% | −2.0*—−3.2% | 8.6*+29.2%13.1% | −0.9*—−1.4% | −6.0−2442%−10.1% | −3.6*—−5.9% | 6.6*—10.5% | −4.1*—−7.1% | 0.3—0.4% | −0.0*—−0.0% | −7.4*—−13.8% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Mesa Laboratories, Inc. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$203 M82%+2.5%
- Consumables$146 M59%+5.2%
- Hardware and Software$57 M23%-3.7%
- Service(total)$46 M18%+7.4%
Business segments
- Sterilization and Disinfection Control$102 M41%+8.7%
- Calibration Solutions$54 M22%+3.5%
- Biopharmaceutical Development$49 M20%-0.2%
- Clinical Genomics$45 M18%-3.6%
Source: SEC annual report (XBRL data) · as of Mar 31, 2026
Where Mesa Laboratories, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Mesa Laboratories, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2026Siddhartha Kadia | $6.6 M | $516 K | $2.3 M | $37 (peers $35) |
| 2025Siddhartha Kadia | $6.6 M | $7.9 M | $2.3 M | $50 (peers $33) |
| 2024Siddhartha Kadia | $5.4 M | $78 K | $1.8 M | $46 (peers $43) |
| 2023Siddhartha Kadia | $5.2 M | −$3.6 M | $1.5 M | $72 (peers $46) |
| 2022Siddhartha Kadia | $18.1 M | $16.8 M | $1.5 M | $105 (peers $66) |
Source: SEC proxy statement (Form DEF 14A) · as of Mar 31, 2026
Events at Mesa Laboratories, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Auditor changed 2 · Impairment 1 · Restructuring 1 · Directors and officers 3 · Material agreement 1 · New debt 1 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| New debt | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Impairment | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
H-1B hiring at Mesa Laboratories, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $169 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Manager, Product Management Calibration SolutionsBioengineers and Biomedical Engineers | 1 | $169 K |
Where: Lakewood, CO 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $169 K | 1 |
| FY2023 | 1 | 1 | $160 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Mesa Laboratories, Inc.
Product recalls by Mesa Laboratories, Inc.#
2 recalls since 2015, 10,228 units in the notices that give a number. Medical devices (FDA): 2.
| Date | What and why | Units | Notice |
|---|---|---|---|
| MesaLabs Conductivity Standard Solution, 14 mS/cm, 32 ounces (950 ml). Product No. : 02.0027, 020510 (carton of 6 of 02.0027). Polyethylene bottle Conductivity/TDS Calibrator solutions are a secondary standard solution used for the calibration of conductivity/TDS cells together with conductivity/TDS measurement instruments. The…Mesa Laboratories is recalling Conductivity/TDS Calibrator Solution due to failure to meet product specifications.Medical devicesClass II | 9,900 | Z-2159-2017 | |
| ProSpore 4 mL Ampoule Biological indicator for steam sterilization, contains Geobacillus stearothermophilus, Catalog Number: PS-6-50, contains 50 Ampoules/Box. Product Usage: Biological indicator for steam sterilization at 121 deg C intended for use by a health care provider to accompany products being sterilized through steam…Product resistance has fallen outside of label claim within expiry.Medical devicesClass II | 328 | Z-1104-2017 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | 40 | · | 40 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 40 people | Restructuring planSEC 8-K | “The Restructuring Program includes the elimination of approximately 40 positions, primarily in our Clinical Genomics division, with additional reductions in our corporate functions…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Mesa Laboratories, Inc.#
4 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 9 November 2026automatic update · Nov 9, 2026
Mesa Laboratories, Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $62 million (up 3% from a year earlier) and net income of $4 million (up 75% from a year earlier).
- Reported to the SEC: Restructuringautomatic update · Oct 13, 2026
Mesa Laboratories, Inc. reported on 13 October 2026 (SEC Form 8-K): • Restructuring: A plan to exit or dispose of activities, usually with job cuts. This is the SEC's classification of the filing; the filing itself has the details.
- Layoff notice: 40 peopleautomatic update · Oct 12, 2026
A restructuring plan at Mesa Laboratories, Inc. was announced on 12 October 2026: 40 people affected. Source: SEC filing (8-K Item 2.05).
How Mesa Laboratories, Inc. compares in Scientific Technical Instruments
- Market cap$726 M · higher than 36% of 87
- Revenue$249 M · higher than 38% of 64
- Net margin2.6% · higher than 29% of 60
- Revenue growth3.4% · higher than 47% of 37
- P/E ratio109.1× · lower than 3% of 33
- Price / sales2.9× · lower than 70% of 44
- Price / book3.9× · lower than 54% of 42
- FCF yield5.5% · higher than 87% of 24
Peer comparison · Scientific Technical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Mesa Laboratories, Inc.🇺🇸 | $726 M | 109.1× | 2.6% | +3.4% |
| Keyence Corporation🇯🇵 | $134.1 B | 44.5× | 38.1% | — |
| Keysight Technologies, Inc.🇺🇸 | $64.3 B | 51.0× | 19.1% | +8.0% |
| Garmin Ltd.🇺🇸 | $54.9 B | 27.2× | 25.6% | +15.1% |
| Coherent Corp.🇺🇸 | $41.2 B | 42.8× | 12.2% | +22.5% |
| Hexagon AB (publ)🇸🇪 | $32.8 B | 44.9× | 11.4% | — |
| Teledyne Technologies Incorporated🇺🇸 | $28.0 B | 27.3× | 15.8% | +7.9% |
| MKS Instruments, Inc.🇺🇸 | $21.0 B | 71.2× | 7.5% | — |
| Lasertec Corporation🇯🇵 | $19.8 B | 34.5× | 33.7% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending March-2026
- Balance sheet:
- As of March-2026
- Employees:
- As on June-2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Mesa Laboratories, Inc.? Verify and update this profile — free
Show Mesa Laboratories, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.